CDKN2A and hereditary leiomyomatosis and renal cell cancer: For example, it was shown that HLRCC patients exhibit a CpG island hypermethylation phenotype and the hypermethylation of the tumour suppressor cyclin-dependent kinase inhibitor 2A [70], encoding for p16, involved in cell cycle regulation and senescence activation [71, 72].